Multicenter prospective trial after first unsuccesful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistance of molecular remission after stopping tyrosine kinase inhibitors a second time

Trial Profile

Multicenter prospective trial after first unsuccesful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistance of molecular remission after stopping tyrosine kinase inhibitors a second time

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms NAUT
  • Most Recent Events

    • 08 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top